Session » Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1055

A Combination of Self-Reported Symptoms and ACPA Testing Can Identify Individuals with Previously Undiagnosed Inflammatory Arthritis in a Health-Fair Setting

9:00AM-11:00AM: Abstract Number: 1046

Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1037

Biosimilar Knowledge Among US Rheumatologists – a Survey

9:00AM-11:00AM: Abstract Number: 1036

Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1057

Budgetary Impact Analysis of Real-World Dosing Patterns in Matched Cohorts of Rheumatoid Arthritis Patients Treated with Infliximab or Golimumab Intravenous Anti-TNF Medications

9:00AM-11:00AM: Abstract Number: 1033

Burden of Illness in Patients with RA and Anti-Cyclic Citrullinated Peptide Positivity

9:00AM-11:00AM: Abstract Number: 1043

Comparison of the Costs for Hyaluronic Acid and Total Knee Arthroplasty in the Treatment of OA for the Blue Cross/Blue Shield Patient Population

9:00AM-11:00AM: Abstract Number: 1047

Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing

9:00AM-11:00AM: Abstract Number: 1059

Cost-Effectiveness of Tai Chi Versus Physical Therapy for Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1031

Developing a Multi-Phase Claims-Based Algorithm to Facilitate the Study of Drug Exposure during Pregnancy

9:00AM-11:00AM: Abstract Number: 1048

Efficacy of Educating Visiting Pharmacists Regarding Drug Administration for Patients with Rheumatoid Arthritis Who Poorly Adhere to Treatment Regimens

9:00AM-11:00AM: Abstract Number: 1056

Evolution of Health Care Consumption in the Knee and Hip Osteoarthritis Long Term Assessment Cohort, a French Population Based Cohort of Symptomatic Knee and/or Hip OA Patients

9:00AM-11:00AM: Abstract Number: 1030

Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1054

Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis

9:00AM-11:00AM: Abstract Number: 1049

Heart Rate Variability Testing with Autonomic Nervous System Optimization: Could It Change the Course of Spending for Rheumatoid Arthritis Patients in the U.S.? an Exploratory Minimal Model Analysis

9:00AM-11:00AM: Abstract Number: 1038

Impact of Patient Support Program Utilization on Patient Activation Measure Scores Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1053

Impact of Step Therapy Protocols on North Carolina Rheumatologists’ Job Satisfaction and the Quality of Care Received By Their Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1039

Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity

9:00AM-11:00AM: Abstract Number: 1044

Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1040

Perceptions of US Community Rheumatologists on Biosimilars

9:00AM-11:00AM: Abstract Number: 1034

Presence of Anti-Cyclic Citrullinated Peptide Antibodies Is Associated with Better Treatment Response to Abatacept but Not to TNF Inhibitors in Patients with RA: A Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1050

Prevalence and Predictors of Knee Replacement Overuse and Underuse in the US

9:00AM-11:00AM: Abstract Number: 1041

Real-World Utilization of Biosimilars for Management of Rheumatoid Arthritis (RA) in the US

9:00AM-11:00AM: Abstract Number: 1042

Remote Management of Osteoporosis Screening and Treatment in US Veterans Using a Bone Health Team: A Cost-Effectiveness Analysis

9:00AM-11:00AM: Abstract Number: 1035

Risk of Hospitalization Among RA Patients with Multiple Autoimmune Co-Morbidities Differs By DMARD Treatment

9:00AM-11:00AM: Abstract Number: 1052

Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor

9:00AM-11:00AM: Abstract Number: 1051

Telemedicine for Rheumatoid Arthritis in the Alaska Native Population

9:00AM-11:00AM: Abstract Number: 1045

The Potential Value of a Shared Decision-Making Intervention for Choices Regarding Triple Therapy in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1032

Trends in Hospitalizations Following Heart Failure Diagnosis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1058

Variation in DMARD Therapy Following Methotrexate Failure for Newly-Identified Rheumatoid Arthritis in a National Veterans Health Administration Cohort

9:00AM-11:00AM: Abstract Number: 1029

What to Measure after Arthroplasty? Confirmation of a Core Domain Set

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].